India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change

Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.

India's clinical trials segment provides opportunities • Source: Shutterstock

If you’re entering India for clinical trials, then don’t do it half-heartedly, just 'go all in', but be careful about the initial choice of disease areas – that’s the advice Novartis’s head, global clinical operations, Badhri Srinivasan had for his peer at Amgen, Inc. which appears to be evaluating opportunities in the world's most populous country.

Responding to a question from Amgen’s senior vice president, global development, Rob Lenz at a recent summit, Srinivasan said that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Nicox Plots US Submission After Another Phase III Glaucoma Win

21 Aug 2025

• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

20 Aug 2025

• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

20 Aug 2025

• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

20 Aug 2025

• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

20 Aug 2025

• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.